Notably, it did increase the expression of genes involved in antigen processing and presentation, such as Tap1, Tapbp, and Erap2. Further supporting the AXL/MHC-I link, a study analyzing 94 melanoma tumors, at baseline and after progression under PD-1 inhibitor treatment, found that MHC-I downregulation was associated with PD-1 inhibitor resistance [95]. Here, AXL is linked to melanoma.